HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

The “Chemical Safety Improvement Act of 2013” would reform chemicals regulation in the U.S. by requiring manufacturers to submit safety data and prioritizing high-risk substances for further evaluation by the Environmental Protection Agency. More news in brief.

You may also be interested in...



Coty Projects Slight Q1 Decline, Citing “Drastic Drop” In Nail Segment

Coty is holding off on full-year projections until it gains visibility into the back-to-school and Christmas seasons, but expects first-quarter revenues to be down, largely due to a significant decline in nail-care consumption. The newly public firm looks to offset retailer destocking with innovations across its portfolio, previewed during its fiscal 2013 fourth-quarter and year-end earnings call.

Chemical Safety Improvement Act Promises Stronger EPA Oversight

Introduced by New Jersey Sen. Frank Lautenberg, the Chemical Safety Improvement Act of 2013 would give EPA authority to evaluate chemicals in commerce based on risk to human health and the environment and take action on those deemed unsafe. The bill would update the current Toxic Substances Control Act and potentially impact manufacturers of cosmetic ingredients.

In Brief

FDA issued warning letters Sept. 21 to two skin-care companies it says are making unapproved drug claims. More news in brief.

Related Companies

UsernamePublicRestriction

Register

RS018550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel